Condition
Giant Cell Tumors
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06331104CompletedPrimary
Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone
NCT05542524CompletedPrimary
Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour
NCT02948088CompletedPrimary
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
NCT00680992Phase 2Completed
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
Showing all 4 trials